Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of BMS-986158 in Subjects With Select Advanced Cancers (BET)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02419417
Recruitment Status : Recruiting
First Posted : April 17, 2015
Last Update Posted : October 9, 2019
Sponsor:
Information provided by (Responsible Party):
Bristol-Myers Squibb

Brief Summary:
The purpose of this study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of BMS-986158 in subjects with select advanced cancers

Condition or disease Intervention/treatment Phase
Advanced Tumors Drug: BMS-986158 Biological: Nivolumab Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 417 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination With Nivolumab in Subjects With Selected Advanced Solid Tumors or Hematologic Malignancies
Actual Study Start Date : June 5, 2015
Estimated Primary Completion Date : July 12, 2023
Estimated Study Completion Date : July 12, 2023

Resource links provided by the National Library of Medicine

Drug Information available for: Nivolumab

Arm Intervention/treatment
Experimental: Monotherapy Treatment
Patients treated at various doses and schedules
Drug: BMS-986158
Specified dose on specified days

Experimental: Combination Therapy
Patients treated at selected doses and schdules
Drug: BMS-986158
Specified dose on specified days

Biological: Nivolumab
Specified dose on specified days
Other Names:
  • BMS-936558
  • Opdivo




Primary Outcome Measures :
  1. Number of Adverse Events (AEs) [ Time Frame: Up to 4 years ]
  2. Number of Serious Adverse Events (SAEs) [ Time Frame: Up to 4 years ]
  3. Number of AEs leading to discontinuation [ Time Frame: Up to 4 years ]
  4. Number of laboratory test toxicity grade shifting from baseline [ Time Frame: Up to 4 years ]

Secondary Outcome Measures :
  1. Best Overall Response [ Time Frame: Up to 4 years ]
  2. Objective Response Rate (ORR) [ Time Frame: Up to 4 years ]
  3. Duration of Response [ Time Frame: Up to 4 years ]
  4. Maximum observed plasma concentration (Cmax) [ Time Frame: Up to 4 years ]
  5. Time of maximum observed plasma concentration (Tmax) [ Time Frame: Up to 4 years ]
  6. Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) [ Time Frame: Up to 4 years ]
  7. Area under the concentration-time curve in one dosing interval (AUC(TAU)) [ Time Frame: Up to 4 years ]
  8. Apparent terminal phase half-life (T-HALF) [ Time Frame: Up to 4 years ]
  9. Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) [ Time Frame: Up to 4 years ]
  10. Apparent total body clearance, reported only for parent, not for metabolite (CLT/F) [ Time Frame: Up to 4 years ]
  11. Apparent volume of distribution of terminal phase, reported only for parent, not for metabolite (Vz/F) [ Time Frame: Up to 4 years ]
  12. Minimum observed concentration within a dosing interval (Cmin) [ Time Frame: Up to 4 years ]
  13. Concentration at the end of a dosing interval (Ctau) [ Time Frame: Up to 4 years ]
  14. Trough observed plasma concentration (this includes predose concentrations (C0) and concentrations at the end of dosing interval (Ctau)) (Ctrough) [ Time Frame: Up to 4 years ]
  15. Degree of Fluctuation or Fluctuation Index ([Cmax-Cmin)/Css-avg]) [ Time Frame: Up to 4 years ]
  16. [Cmax - Cmin] / Cmin; to be calculated at steady-state (Swing) [ Time Frame: Up to 4 years ]
  17. Accumulation Index (AI) [ Time Frame: Up to 4 years ]
    Ratio of an exposure measure at steady-state to that after the first dose (exposure measure includes AUC(TAU), Cmax and Ctau)

  18. Effective elimination half-life that explains the degree of accumulation observed for a specific exposure measure (T-HALFeff) [ Time Frame: Up to 4 years ]
  19. Ratio of metabolite Cmax to parent Cmax, corrected for molecular weight (MR_Cmax) [ Time Frame: Up to 4 years ]
  20. Ratio of metabolite AUC(0-T) to parent AUC(0-T), corrected for molecular weight (MR_AUC(0-T)) [ Time Frame: Up to 4 years ]
  21. Ratio of metabolite AUC(INF) to parent AUC(INF), corrected for molecular weight (following single dose only) (MR_AUC(INF)) [ Time Frame: Up to 4 years ]
  22. Ratio of metabolite AUC(TAU) to parent AUC(TAU), corrected for molecular weight (MR_AUC(TAU)) [ Time Frame: Up to 4 years ]
  23. Electrocardiogram (ECG) QT (time of ventricular activity including both depolarization and repolarization) Interval [ Time Frame: Up to 4 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

  • Must have select advanced cancers with specific genetic profiles
  • Must have received appropriate standard of care
  • At least one measurable lesion at baseline
  • Expected to have life expectancy of at least 3 months
  • Eastern Cooperative Oncology Group (ECOG) of 0 to 1

Exclusion Criteria:

  • Concomitant second malignancies
  • Uncontrolled or significant cardiovascular disease
  • Inadequate bone marrow function
  • Chronic gastrointestinal illness
  • Prior treatment with Bromodomain and Extra-Terminal (BET) inhibitor

Other protocol defined inclusion/exclusion criteria could apply


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02419417


Contacts
Layout table for location contacts
Contact: Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email: Clinical.Trials@bms.com
Contact: First line of the email MUST contain NCT# and Site #.

Locations
Layout table for location information
United States, California
City Of Hope National Medical Center Recruiting
Duarte, California, United States, 91010
Contact: Mihaela Cristea, Site 0004    626-359-8111      
Local Institution Not yet recruiting
La Jolla, California, United States, 92093-0987
Contact: Site 0035         
United States, Colorado
University Of Colorado Recruiting
Aurora, Colorado, United States, 80045
Contact: Jennifer Diamond, Site 0020    720-848-0643      
United States, Massachusetts
Dana Farber Cancer Institute. Recruiting
Boston, Massachusetts, United States, 02215
Contact: Geoffrey Shapiro, Site 0033    617-632-6623      
United States, Oregon
Oregon Health & Science University Recruiting
Portland, Oregon, United States, 97239
Contact: Matthew Taylor, Site 0023    503-494-6594      
United States, Pennsylvania
Univ. Of Pa Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Thomas Karasic, Site 0029    215-220-9668      
United States, South Carolina
Institute for Translational Oncology Research-ITOR Recruiting
Greenville, South Carolina, United States, 29605
Contact: William Edenfield, Site 0001    864-679-3926      
Australia, Victoria
Nucleus Network Recruiting
Melbourne, Victoria, Australia, 3004
Contact: Jason Lickliter, Site 0006    +61390688960      
Canada, Ontario
The Ottawa Hospital Cancer Centre Recruiting
Ottawa, Ontario, Canada, K1H 8L6
Contact: John Hilton, Site 0003    613737770073955      
Local Institution Withdrawn
Toronto, Ontario, Canada, M5G 1X6
France
Local Institution Not yet recruiting
Lyon Cedex 08, France, 69373
Contact: Site 0025         
Local Institution Not yet recruiting
Paris Cedex 5, France, 75248
Contact: Site 0026         
Local Institution Recruiting
Villejuif, France, 94800
Contact: Site 0024         
Spain
Local Institution Not yet recruiting
Barcelona, Spain, 08035
Contact: Site 0030         
Local Institution Recruiting
Madrid, Spain, 28050
Contact: Site 0019         
Local Institution Not yet recruiting
Pamplona, Spain, 31008
Contact: Site 0018         
United Kingdom
Local Institution Not yet recruiting
Whitchurch, United Kingdom, CF14 2TL
Contact: Site 0032         
Sponsors and Collaborators
Bristol-Myers Squibb
Investigators
Layout table for investigator information
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb

Additional Information:
Layout table for additonal information
Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT02419417     History of Changes
Other Study ID Numbers: CA011-001
2015-000324-29 ( EudraCT Number )
First Posted: April 17, 2015    Key Record Dates
Last Update Posted: October 9, 2019
Last Verified: October 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Nivolumab
Antineoplastic Agents, Immunological
Antineoplastic Agents